Skip to content

EBIT at other companies

Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$112.33M-54.4%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-$24.22M+10.7%
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
-$132.29M+5.2%
uniQure logo
uniQureQURE
-$45.72M-16.2%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-$3.65M+81.1%
Eli Lilly logo
Eli LillyLLY

Other financials

Income statement

See full
Operating income-$130.4M+41.1%
Net income-$130.5M+41.1%
EPS (diluted)-$0.88+59.4%

Balance sheet

See full
Cash & equivalents$277.1M+170%
Total debt$286.2M+706%
Total equity$129.5M-50.1%
Total assets$466.4M+1.6%

Cash flow

See full
Operating cash flow-$149.9M+9.2%
CapEx--100%
Free cash flow-$149.9M+9.5%

Valuation

See full
Market cap$2.25B-48.1%

Returns & leverage

See full
Return on equity-333%+17.9pp
Debt / equity2.2×+2.1×
Current ratio7.4×+5.1×

Where this comes from

Calculated from Biohaven’s reported figures.

Plus components not separately reported this period.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biohaven's EBIT?
Biohaven (BHVN) reported EBIT of -$130.43M in Q1 2026.
How has Biohaven's EBIT changed year-over-year?
Biohaven's EBIT increased by 41.1% year-over-year, from -$221.56M to -$130.43M.
What is the long-term trend for Biohaven's EBIT?
Over 3 years (2022 to 2025), Biohaven's EBIT has grown at a 9.5% compound annual growth rate (CAGR), from -$567.93M to -$745.38M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.